Premium
Effectiveness of Drugs in Routine Care: A Model for Sequential Monitoring of New Medicines Using Dronedarone as Example
Author(s) -
Cars T,
Lindhagen L,
Malmström RE,
Neovius M,
Schwieler J,
Wettermark B,
Sundström J
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.751
Subject(s) - dronedarone , medicine , health care , clinical trial , drug , intensive care medicine , postmarketing surveillance , risk analysis (engineering) , pharmacology , adverse effect , amiodarone , economics , economic growth , atrial fibrillation
Although there is no doubt about the scientific value of randomized controlled clinical trials, they are usually conducted in selected populations different from those treated in clinical practice. Therefore, it is important to optimize real‐time postmarketing evaluation of the effectiveness, safety, and cost of new drugs. Using electronic health records and administrative health databases from a well‐defined region with universal access to healthcare, we have built a framework for real‐time sequential monitoring of the effectiveness of newly marketed drugs in routine care. We chose the antiarrhythmic agent dronedarone as the study drug and flecainide as the comparator drug for illustration of the model. We demonstrate that this model produces consistent results with increasing precision over time as data accumulates in the clinical systems. We believe that use of this model at the introduction of new drugs can provide complementary evidence, especially in settings of adaptive licensing of new drugs.